Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats

Journal of Veterinary Medical Science

Volumn 71, Issue 9, 2009, Pages 1151-1159

  Shah, Syed Sher ^a   Sasaki, Kazuaki ^a   Hayashi, Yuhei ^a   Motoyama, Seiko ^a   Helmi, Abdou Rania ^a   Khalil, Waleed Fathy ^a   Shimoda, Minoru ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Cimetidine; CYP3A; Enzyme inhibition; Feline; Ketoconazole

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CIMETIDINE; CYTOCHROME P450 3A; ENZYME INHIBITOR; ERYTHROMYCIN; HYPNOTIC SEDATIVE AGENT; KETOCONAZOLE; MIDAZOLAM;

ANIMAL; AREA UNDER THE CURVE; ARTICLE; BLOOD; CAT; DOSE RESPONSE; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; HALF LIFE TIME; LIVER MICROSOME;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CATS; CIMETIDINE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ERYTHROMYCIN; FEMALE; HALF-LIFE; HYPNOTICS AND SEDATIVES; KETOCONAZOLE; MICROSOMES, LIVER; MIDAZOLAM;

FELIDAE;

EID: 70349991905     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.71.1151     Document Type: Article

References (32)

1. Benet, L. Z., Kroets, L. and Sheiner, L. B. 1996. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. pp. 3-27. In: Googman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed., (Hardman, J. G. and Limbird, L. E. eds.), McGraw-Hill, New York.
2. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
3. Chien, J. Y., Lucksiri, A., Ernest II C. S., Gorski, C., Wrighton, S. A. and Hall, S. A. 2006. Stochastic predication of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug. Metab. Dispos. 34: 1208-1219.
4. Daigle, J. C., Hosgood, G., Foil, C. S. and Hunter, R. P. 2001. Effect of cimetidine on pharmacokinetics of orally administered cyclosporine in healthy dogs. Am. J. Vet. Res. 62: 1046-1050.
5. Dahlinger, J., Gregory, C. and Bea, J. 1998. Effect of ketoconazole on cyclosporine dose in healthy dogs. Vet. Surg. 27: 64-68.
6. Edstein, M. D., Prasitthipayong, A., Sabchareon, A., Chongsuhajaisiddhi, T. and Webester, H. K. 1990. Simultaneous measurement of quinine and quinidine in human plasma, whole blood, and erythrocytes by high-performance liquid chromatography with fluorescence detection. Ther. Drug Monit. 12: 493-500.
7. Gibbs, M. A., Thummel, K. E., Shen, D. D. and Kunze, K. L. 1999. Inhibition of CYP3A in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug. Metab. Dispos. 27: 180-187.
8. Guengerich, F. P. 1999. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39: 1-17.
9. Johnson, L. M., Lankford, S. M. and Bai, S. A. 1995. The influence of cimetidine on the pharmacokinetics of the enantiomers of verapamil in the dog during multiple oral dosing. J. Vet. Pharmacol. Therap. 18: 117-123.
10. Kuroha, M., Kayaba, H., Kishimoto, S., Khalil, W. F., Shimoda, M. and Kokue, E. 2002. Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs. J. Pharm. Sci. 91: 868-873.
11. Kuroha, M., Azumano, A., Kuze, Y., Shimoda, M. and Kokue, E. 2002. Effect of multiple dosing of Ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. Drug. Metab. Dispos. 30: 63-68.
12. Kuroha, M., Kuze, Y., Shimoda, M. and Kokue, E. 2002. In vitro characterization of the inhibitory effects of Ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. Am. J. Vet. Res. 63: 900-905.
13. Kuroha, M., Shirai, Y. and Shimoda, M. 2004. Multiple oral dosing of Ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs. J. Vet. Pharmacol. Therap. 27: 355-359.
14. Myre, S. A., Schoeder, T. J., Grund, V. R., Wandstrat, T. L., Nicelv, P. G., Pesce, A. J. and First, M. R. 1991. Critical ketoconazole dosage range for cyclosporine clearance inhibition in the dog. Pharmacology 43: 233-241.
15. Martinez, C., Albet, C., Agundez, J. A., Herrero, E., Carrillo, J. A., Marquez, M., Benitez, J. and Ortiz, J. A. 1999. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin. Parmacol. Ther. 65: 369-376.
16. McAnulty, J. F. and Lensmeyer G. L. 1999. The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. Vet. Surg. 28: 448-455.
17. Newton, D. J., Wang, R. W. and Lu, A. Y. 1995. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug. Metab. Dispos. 23: 154-158.
18. Omura, T. and Sato, R. 1964. The carbon monoxide binding pigment of liver microsomes. J. Biol. Chem. 239: 2370-2378.
19. Pichard, L., Fabre, I., Fabre, G., Domergue, J., Saint Aubert, B., Mourad, G. and Maurel, P. 1990. Cyclosporine A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (Cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18: 595-606.
20. Plumb, D. C. 1999. Ketoconazole. pp. 365-369. In: Veterinay Drug Handbook, 3rd ed. (Plumb, D. C. ed.), Iowa State Press, Ames.
21. Plumb, D. C. 1999. Cimetidine. pp. 134-137. In: Veterinay Drug Handbook, 3rd ed. (Plumb, D. C. ed.), Iowa State Press, Ames.
22. Shah, S. S., Sanda, S., Regmi, N. L., Sasaki, K. and Shimoda, M. 2007. Characterization of cytochrome P450-mediated drug metabolism in cats. J. Vet. Pharmacol. Therap. 30: 422-428
23. Trepanier, L. A. 2006. Cytochrome P450 and its role in veterinary drug interaction. Vet. Clin. North Am. Small Anim. Pract. 36: 975-985.
24. Van der Hoeven, T. A. and Coon, M. J. 1974. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J. Biol. Chem. 249: 6302-6310.
25. Von Moltke L. L., Greenblatt D. J., Schmider J., Duan S. X., Wright C. E., Harmatz, J. S. and Shader, R. I. 1996. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. Clin. Pharmacol. 36: 783-791.
26. Wang, J. S., Wen, X., Backman, J. T., Taavitsainen, P., Neuvonen, P. J. and Kivisto, K. T. 1999. Midazolam alpha-hydroxylation by human liver microsomes in vitro: Inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol. Toxicol. 85: 157-161.
27. Wrighton, S. A., Vandenbranden, M., Stevens, J. C., Shipley, L. A., Ring, B. J., Rettie, A. E. and Cashman, J. R. 1993. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 25: 453-484.
28. Wrighton, S. A. and Ring, B. J. 1994. Inhibition of human CYP3A catalyzed 1'-hydroxymidazolam formation by ketoconazole, nifedipine, erythromycin, cimitidine, and nizatidine. Pharm. Res. 11: 921-924.
29. Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T. 1981. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4: 879-885.
30. Yamano, K., Yamamoto, K., Katashima, M, Kotaki, H., Takedomi, S., Matsuo, H., Ohtani, H., Sawada, Y. and Iga, T. 2001. Predication of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab. Dispos. 29: 443-452.
31. Zhao, P., Kunze, K. L. and Lee, C. A. 2005. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab. Dispos. 33: 853-861.
32. Zuber, R., Anzenbacherova, E. and Anzenbacher, P. 2002. Cytochrome P450 and experimental models of drug metabolism. J. Cellular Mol. Med. 6: 189-198.